Healthcare
Filter News
Found 20,071 articles
-
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
4/5/2024
Predicine, Inc. A leading precision oncology company, announced that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.
-
Sanofi has in principle reached a settlement related to its discontinued heartburn drug Zantac, though the French pharma did not disclose the financial terms of the deal.
-
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
4/4/2024
Johnson & Johnson announced that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo taking place April 6-8, 2024, in Atlanta, Georgia.
-
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
4/4/2024
Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
-
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
4/4/2024
Delcath Systems, Inc. announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March 2024.
-
China Medical University Hospital (CMUH) Explores ' BrainHealth ' to Scrutinize Dementia within a Minute
4/4/2024
In clinical practice, neurologists scrutinize dementia patients with using numerous tools, including medical history, blood tests, cognitive testing, mental assessment, medical imaging and electro-physiological signal testing.
-
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4/4/2024
Werewolf Therapeutics, Inc. announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists taking place May 3-7 in Chicago, Illinois.
-
American Skin Association Announces New Board Member Joseph F. Merola, MD, MMSc, FAAD, FACR
4/4/2024
American Skin Association announced that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
-
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
4/4/2024
Grifols announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation, the first for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
4/4/2024
Blueprint Medicines Corporation, announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development
4/4/2024
Caris Discovery™, the therapeutic research arm of Caris Life Sciences®, the leading next-generation AI TechBio company and precision medicine pioneer, announced a multi-year strategic partnership with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.
-
Revolution Medicines to Participate in Upcoming April 2024 Investor Conferences
4/4/2024
Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
-
Strategic Acquisition Opportunity: Biotechnology Intellectual Property of Civetta Therapeutics, LLC Now Open for Bids
4/4/2024
The Assignee of Civetta Therapeutics, LLC, a trailblazer in the field of biotechnology with a focus on β-propeller protein research, is inviting bids for the company's rich portfolio of intellectual property.
-
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
4/4/2024
Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that it has received 510 clearance from the U.S. Food and Drug Administration for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge.
-
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
4/4/2024
Mural Oncology plc announced that on April 1, the Company granted to four newly hired employees non-statutory stock options to purchase an aggregate of 25,675 ordinary shares of the Company and restricted stock units with respect to an aggregate of 13,825 ordinary shares of the Company.
-
China Medical University Hospital (CMUH) Launches "Intelligent Microbiome Evaluation- iME" to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health
4/3/2024
Gastrointestinal examinations can be invasive or non-invasive. Stool tests can be associated with limitations such as the amount of pathogens present being too low for culture or detection, resulting in negative PCR results.
-
China Medical University Hospital (CMUH) Inventing "Intelligent Urine Sediment Morphology Analysis, IUSMA" to Find Chronic Glomerulonephritis in Just 10 Minutes
4/3/2024
The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals, and bacteria, while urine bacterial culture and pathological diagnostics may require an additional week.
-
PreludeDx™ to Present New Data in DCIS and Early-Stage Invasive Breast Cancer at the American Society of Breast Surgeons Annual Meeting
4/3/2024
Prelude Corporation announced that data will be highlighted in a Quickshot Scientific Session and poster presentation at the 25th American Society of Breast Surgeons Annual Meeting, to be held on April 10 - 14, 2024 at the Orlando World Center Marriott.
-
CMUH (Taiwan) Launches "Intelligent Sepsis Early Prediction System (ISEPS)," Detecting Sepsis in One Minute Only
4/3/2024
In conventional practice, a blood culture report wouldn't be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response.
-
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
4/3/2024
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, announced a planned poster presentation at the upcoming American Academy of Neurology 2024 Annual Meeting, to be held April 13 – 18, 2024, in Denver, Colorado and online.